VivoSeq
Gastroenterology

Liver Disease

201

Pipeline Programs↗

24

Active Trials↗

87

Companies Involved↗

Liver Disease is a highly competitive landscape with 201 programs across 87 companies. The most active players are Regeneron, Risen (Suzhou) Pharma Tech Co., Ltd., Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 87 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

19/100

Mech. Concentration

2/100

Completion Rate

82/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

2 programs

Phase 1R

Risen (Suzhou) Pharma Tech Co., Ltd.

2 programs

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

2 programs

Phase 1P

Puma Biotechnology, Inc.

1 program

Phase 1X

Xiamen Amoytop Biotech Co., Ltd.

1 program

Phase 1B

Beijing InnoCare Pharma Tech Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical21

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Defibrotide

Jazz Pharmaceuticals

Metreleptin

Chiesi Farmaceutici S.p.A.

Metformin

EMD Serono

Azathioprine

Legacy Health System

Phase 144

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Gilteritinib

Astellas

Fluzoparib

Risen (Suzhou) Pharma Tech Co., Ltd.

Afatinib

Boehringer Ingelheim

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 235

Cagrilintide

Novo Nordisk

Pemvidutide

Altimmune

Eltrombopag

GSK

Lactulose

Solvay Pharmaceuticals

Prednisone

Roxane Laboratories

Phase 314

Tirzepatide

Eli Lilly

Retatrutide

Eli Lilly

Filgrastim

Eastern Cooperative Oncology Group

Gabapentin

Viatris Specialty LLC

Propranolol

Wyeth-Lederle Vaccines

Approved87

Istradefylline

Kyowa Kirin Co., Ltd.

Fruquintinib

Takeda

Binimetinib

Pfizer

Tepotinib

EMD Serono

Entecavir

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Analysis

Modality Breakdown

92%

Small molecule

192 of 209 classified programs — the dominant modality here.

8%ALL OTHERSPeptide105%Protein / enzyme31%Vaccine2<1%Monoclonal antibody1<1%RNA therapy1<1%

Small molecule leads; the ring shows all 209 classified programs, each share of the total. Modality classified for 100% of 222 pipeline programs.

Analysis

Trial Status

121

clinical trials

Completed61 · 50%
Unknown status20 · 17%
Recruiting19 · 16%
Terminated8 · 7%
Withdrawn5 · 4%
Not yet recruiting4 · 3%
Other4 · 3%

Clinical Trials

Trial Activity

121 trials

COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
Recruiting·UUniversity of Oxford·Phase 1·NCT06704516·10 enrolled
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
Recruiting·GSK logoGSK·Phase 2·NCT06613698·393 enrolled
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Recruiting·—·Phase 2·NCT06355310·40 enrolled
PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease
Recruiting·UUniversidad Autonoma de Nuevo Leon·Phase 2·NCT06861478·182 enrolled
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Recruiting·Altimmune logoAltimmune·Phase 2·NCT07009860·100 enrolled
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Recruiting·HHospital Universitari Vall d'Hebron Research Institute·Phase 3·NCT06434753·300 enrolled
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Recruiting·—·Phase 4·NCT06449339·474 enrolled
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07214870·60 enrolled
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
Recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05195450·200 enrolled
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT06891365·48 enrolled
China Registry for Genetic / Metabolic Liver Diseases
Recruiting·—·N/A·NCT03131427·20,000 enrolled
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Recruiting·Takeda logoTakeda·Phase 3·NCT05677971·160 enrolled
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
Recruiting·NNorthSea Therapeutics B.V.·Phase 2·NCT05919680·36 enrolled
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Recruiting·Takeda logoTakeda·Phase 3·NCT06165341·50 enrolled
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT05478083·36 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)